What is AXP1275 used for?

AXP1275 is indicated for Treatment of relapsed or refractory follicular lymphoma.

AXP1275 is developed by Axikin Pharmaceuticals, Inc..

What are the side effects of AXP1275?

Common side effects include Neutropenia, Thrombocytopenia, Anemia.

Last reviewed 2026-04-23 · How we verify

AXP1275

Axikin Pharmaceuticals, Inc. · Phase 2 active Small molecule

AXP1275 is a small molecule inhibitor of the PI3K delta subunit.

AXP1275 is a small molecule inhibitor of the PI3K delta subunit. Used for Treatment of relapsed or refractory follicular lymphoma.

At a glance

Generic name	AXP1275
Sponsor	Axikin Pharmaceuticals, Inc.
Drug class	PI3K delta inhibitor
Target	PI3K delta
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

By inhibiting the PI3K delta subunit, AXP1275 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.

Approved indications

Treatment of relapsed or refractory follicular lymphoma

Common side effects

Neutropenia
Thrombocytopenia
Anemia

Key clinical trials

A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AXP1275 CI brief — competitive landscape report
AXP1275 updates RSS · CI watch RSS
Axikin Pharmaceuticals, Inc. portfolio CI